Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

A systematic approach to understand the mechanism of action of the bisthiazolium compound T4 on the human malaria parasite, Plasmodium falciparum.

Le Roch KG, Johnson JR, Ahiboh H, Chung DW, Prudhomme J, Plouffe D, Henson K, Zhou Y, Witola W, Yates JR, Mamoun CB, Winzeler EA, Vial H.

BMC Genomics. 2008 Oct 30;9:513. doi: 10.1186/1471-2164-9-513.

2.

Potent antihematozoan activity of novel bisthiazolium drug T16: evidence for inhibition of phosphatidylcholine metabolism in erythrocytes infected with Babesia and Plasmodium spp.

Richier E, Biagini GA, Wein S, Boudou F, Bray PG, Ward SA, Precigout E, Calas M, Dubremetz JF, Vial HJ.

Antimicrob Agents Chemother. 2006 Oct;50(10):3381-8.

3.

Comparison of the cellular and biochemical properties of Plasmodium falciparum choline and ethanolamine kinases.

Alberge B, Gannoun-Zaki L, Bascunana C, Tran van Ba C, Vial H, Cerdan R.

Biochem J. 2009 Dec 14;425(1):149-58. doi: 10.1042/BJ20091119.

PMID:
19845508
4.

Effect of a bis-thiazolium compound on the biosynthesis of Plasmodium falciparum phospholipids.

Ahiboh H, Djaman AJ, Yapi FH, Edjeme-Aké A, Hauhouot-Attoungbré ML, Yayo ED, Monnet D.

J Enzyme Inhib Med Chem. 2009 Aug;24(4):911-7. doi: 10.1080/14756360802447974.

PMID:
19235542
5.

A chemical proteomics approach for the search of pharmacological targets of the antimalarial clinical candidate albitiazolium in Plasmodium falciparum using photocrosslinking and click chemistry.

Penarete-Vargas DM, Boisson A, Urbach S, Chantelauze H, Peyrottes S, Fraisse L, Vial HJ.

PLoS One. 2014 Dec 3;9(12):e113918. doi: 10.1371/journal.pone.0113918. eCollection 2014.

6.

Dynamic RNA profiling in Plasmodium falciparum synchronized blood stages exposed to lethal doses of artesunate.

Natalang O, Bischoff E, Deplaine G, Proux C, Dillies MA, Sismeiro O, Guigon G, Bonnefoy S, Patarapotikul J, Mercereau-Puijalon O, Coppée JY, David PH.

BMC Genomics. 2008 Aug 18;9:388. doi: 10.1186/1471-2164-9-388.

7.

Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate.

Wein S, Maynadier M, Bordat Y, Perez J, Maheshwari S, Bette-Bobillo P, Tran Van Ba C, Penarete-Vargas D, Fraisse L, Cerdan R, Vial H.

Br J Pharmacol. 2012 Aug;166(8):2263-76. doi: 10.1111/j.1476-5381.2012.01966.x.

8.

Unraveling the mode of action of the antimalarial choline analog G25 in Plasmodium falciparum and Saccharomyces cerevisiae.

Roggero R, Zufferey R, Minca M, Richier E, Calas M, Vial H, Ben Mamoun C.

Antimicrob Agents Chemother. 2004 Aug;48(8):2816-24.

9.

Towards a proteomic definition of CoArtem action in Plasmodium falciparum malaria.

Makanga M, Bray PG, Horrocks P, Ward SA.

Proteomics. 2005 May;5(7):1849-58.

PMID:
15832369
10.
11.

Chloroquine mediates specific proteome oxidative damage across the erythrocytic cycle of resistant Plasmodium falciparum.

Radfar A, Diez A, Bautista JM.

Free Radic Biol Med. 2008 Jun 15;44(12):2034-42. doi: 10.1016/j.freeradbiomed.2008.03.010. Epub 2008 Mar 20.

PMID:
18397762
12.

Discovery of gene function by expression profiling of the malaria parasite life cycle.

Le Roch KG, Zhou Y, Blair PL, Grainger M, Moch JK, Haynes JD, De La Vega P, Holder AA, Batalov S, Carucci DJ, Winzeler EA.

Science. 2003 Sep 12;301(5639):1503-8. Epub 2003 Jul 31.

13.

The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum.

Bozdech Z, Llinás M, Pulliam BL, Wong ED, Zhu J, DeRisi JL.

PLoS Biol. 2003 Oct;1(1):E5. Epub 2003 Aug 18.

14.

In vivo transcriptional profiling of Plasmodium falciparum.

Daily JP, Le Roch KG, Sarr O, Fang X, Zhou Y, Ndir O, Mboup S, Sultan A, Winzeler EA, Wirth DF.

Malar J. 2004 Aug 5;3:30.

15.

PG12, a phospholipid analog with potent antimalarial activity, inhibits Plasmodium falciparum CTP:phosphocholine cytidylyltransferase activity.

González-Bulnes P, Bobenchik AM, Augagneur Y, Cerdan R, Vial HJ, Llebaria A, Ben Mamoun C.

J Biol Chem. 2011 Aug 19;286(33):28940-7. doi: 10.1074/jbc.M111.268946. Epub 2011 Jun 25.

17.
18.

Transcriptional profiling of growth perturbations of the human malaria parasite Plasmodium falciparum.

Hu G, Cabrera A, Kono M, Mok S, Chaal BK, Haase S, Engelberg K, Cheemadan S, Spielmann T, Preiser PR, Gilberger TW, Bozdech Z.

Nat Biotechnol. 2010 Jan;28(1):91-8. doi: 10.1038/nbt.1597. Epub 2009 Dec 27.

PMID:
20037583
19.

Antiplasmodial activity and mechanism of action of RSM-932A, a promising synergistic inhibitor of Plasmodium falciparum choline kinase.

Zimmerman T, Moneriz C, Diez A, Bautista JM, Gómez Del Pulgar T, Cebrián A, Lacal JC.

Antimicrob Agents Chemother. 2013 Dec;57(12):5878-88. doi: 10.1128/AAC.00920-13. Epub 2013 Sep 16.

20.

Antimalarial activity of 77 phospholipid polar head analogs: close correlation between inhibition of phospholipid metabolism and in vitro Plasmodium falciparum growth.

Ancelin ML, Calas M, Bompart J, Cordina G, Martin D, Ben Bari M, Jei T, Druilhe P, Vial HJ.

Blood. 1998 Feb 15;91(4):1426-37.

Supplemental Content

Support Center